Showing: 1 - 3 of 3 RESULTS

CytRx Highlights Use of Licensed Drug Aldoxorubicin in Treatment of Former Senate Majority Leader Harry Reid’s Pancreatic Cancer

Reid’s Stage IV Pancreatic Cancer is Reportedly in “Complete Remission” After Combination Immunotherapy That Included NantKwest’s PD-L1 t-haNK, ImmunityBio’s N-803 and Aldoxorubicin

ImmunityBio and NantKwest Announced in May 2020 That They Planned to Commence a Randomized Phase 2 Study of This Experimental Treatment for Pancreatic Cancer

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today highlighted the use of its licensed drug – aldoxorubicin – in the combination immunotherapy used by ImmunityBio, Inc. and NantKwest, Inc. to treat former Senate Majority Leader Harry Reid’s stage IV pancreatic cancer. It was widely reported in June 2020 that former Senator Reid described himself as being in “complete remission” after receiving experimental treatment pioneered by the Chief Executive Officer of ImmunityBio and NantKwest.1

Earlier this year, CytRx highlighted that ImmunityBio and NantKwest announced the initiation of a Phase 2 randomized, two-cohort, open-label study for first and second-line treatment of locally advanced or metastatic pancreatic cancer (QUILT-88). The study received Food and Drug Administration (“FDA”) authorization and was slated to initially enroll 268 subjects across both cohorts. It has been indicated that enrollment was expected to begin in June 2020.

“We wish former Senator Reid the best now that he is reportedly in complete remission and hope that his combination immunotherapy treatment can become the basis for treating other individuals with pancreatic cancer,” said Steven A. Kriegsman, CytRx’s Chairman and CEO. “Although former Senator Reid is only one person and other comprehensive studies and trials are necessary and required, we continue to be encouraged with the progress and results of this promising pancreatic cancer treatment that includes aldoxorubicin.”

CytRx out-licensed global development, manufacturing and commercialization rights for aldoxorubicin to ImmunityBio in 2017. The Company has an agreement with ImmunityBio that can yield up to $343 million in potential milestone payments as well as prospective royalties on sales of aldoxorubicin.

About CytRx Corporation

CytRx Corporation (OTCQB: CYTR) is a biopharmaceutical company with expertise in discovering and developing new therapeutics principally to treat patients with cancer and neurodegenerative diseases. CytRx’s most advanced drug conjugate, aldoxorubicin, is an improved version of the widely used anti-cancer drug doxorubicin and has been out-licensed to ImmunityBio, Inc. In addition, CytRx’s other drug candidate, arimoclomol, was sold to Orphazyme A/S (Nasdaq Copenhagen exchange: ORPHA.CO) in exchange for milestone payments and royalties. Orphazyme is testing arimoclomol in four indications including amyotrophic lateral sclerosis (ALS), Niemann-Pick disease Type C (NPC), Gaucher disease and sporadic Inclusion Body Myositis (sIBM). CytRx Corporation’s website is www.cytrx.com.

About Pancreatic Cancer

Pancreatic cancer kills an estimated 47,000 people annually; it is the fourth leading cause of cancer-related death in the U.S., and 57,600 new cases are expected in 2020. Less than 5% of these patients will live for more than five years after diagnosis, and the median survival prognosis is 5 to 8 months. Pancreatic cancer is a disease in which malignant (cancerous) cells form in the tissues of

Senate cancels work as lawmakers contract virus

WASHINGTON (AP) — The Latest on coronavirus infections hitting President Donald Trump and others in his circle (all times EDT):

12:30 p.m.

Senate Republicans have canceled legislative work until Oct. 19 as the coronavirus sweeps through their ranks and lawmakers increasingly call for comprehensive testing on Capitol Hill.

But Senate Majority Leader Mitch McConnell said in a statement Saturday that confirmation hearings for Supreme Court nominee Amy Coney Barrett are still on.

One by one, President Donald Trump and a series of GOP lawmakers have fallen ill with the virus that has killed more than 208,000 Americans.


Over the last week, many of the politicians who tested positive attended events at which few people wore masks and mingled in the halls and tunnels of the Capitol complex.

Just since Friday morning, Trump, Sen. Thom Tillis of North Carolina, Mike Lee of Utah and Ron Johnson of Wisconsin announced that they have tested positive.

The Senate was to reconvene this week ahead of its confirmation proceedings for Barrett. McConnell has said those hearings, scheduled to begin Oct. 12, are “full steam ahead.”

___

12:15 p.m.

A person familiar with President Donald Trump’s COVID-19 illness says some of his vital signs over the past 24 hours were “very concerning” but they’ve improved since he was admitted to a military hospital.

The person has knowledge of the president’s medical condition but was not authorized to speak publicly and spoke to The Associated Press on condition of anonymity.

It contradicted Trump’s doctors, who said during a press conference Saturday that the president was doing very well and felt as though he could walk out of a military hospital. They said he had not been on oxygen Saturday or when he was with their medical team Friday, and that his symptoms were subsiding.

Trump was admitted to Walter Reed Medical Center on Friday after saying he had contracted COVID-19. First lady Melania Trump also has fallen ill.

The person described the next 48 hours as critical and said there was no clear path yet on a recovery and that it could be days before he was discharged.

___

12 p.m.

President Donald Trump’s doctors say the president is doing well, is fever-free and isn’t having difficulty breathing after contracting the coronavirus.

Doctors said Saturday that Trump was not on supplemental oxygen, and while he had fatigue, nasal congestion and coughing, his symptoms are now resolving and improving.

Dr. Sean Conley, Trump’s physician, refused to say whether Trump had been on supplemental oxygen at any point during his illness, saying he was not on it Saturday or Thursday or Friday while he was with the medical team from Walter Reed Medical Center.

Trump was transferred to the military hospital on Friday afternoon in what doctors say was a precaution after he and first lady Melania Trump tested positive for COVID-19. He has not transferred powers.

Conley says the president has “a lot of work to do” and is doing it.

Doctors say the president told them:

The Senate must act to reauthorize cell transplantation program

Earlier this week, the House passed the TRANSPLANT Act, a bill Rep. Doris MatsuiDoris Okada MatsuiDemocratic lawmaker calls telehealth expansion the ‘silver lining’ of pandemic The Hill’s 12:30 Report: Delegates stage state-centric videos for the roll call Overnight Health Care: Obama leans into Trump criticism on coronavirus | CDC gives 3-month window for COVID-19 immunity MORE (D-Calif.) and I sponsored. It reauthorizes the C.W. Bill Young Cell Transplantation Program and the National Cord Blood Inventory, which will help tens of thousands of Americans of all ages who suffer with diseases like blood cancer, sickle cell anemia, inherited metabolic or immune system disorders and 70 otherwise fatal blood disorders. Every three minutes someone is diagnosed with a blood cancer throughout the nation. This is an especially important issue for seniors, as older Americans are the fastest growing age group of patients needing marrow transplants.

The mission of the national registry is to match patients and donors and to ensure the timely transportation of lifesaving cellular products throughout the United States and around the world. Over the past 30 years, more than 100,000 lifesaving and life-extending transplants have been facilitated through the national registry. Today, more than 22 million volunteers in the national registry are willing to answer the call to save a life. In partnership with other registries around the world, the program has access to more than 35 million donors. The National Marrow Donor Program(NMDP)/Be The Match registry is doing incredible work despite unprecedented challenges. While facing travel restrictions and other pandemic-related logistical dilemmas, this partnership has delivered a second chance at life to more patients than ever before. Surprisingly, the program completed more transplants in June of 2020 than in any single month in the program’s history and has conducted more than 3,000 transplants over the first six months of the public health emergency. This was only made possible by having the status of a federally-authorized program that is recognized by other federal, state and local agencies and foreign governments. Additionally, a CDC waiver allowed international bone marrow couriers to deliver cellular products from abroad to waiting U.S. patients, despite the European pandemic travel restriction, ensuring that more than 350 awaiting U.S. patients got their second chance at life.

Since its inception, the CW Bill Young Cell Transplantation Program has always enjoyed broad bipartisan support in both chambers of Congress because the donations made through this program literally save lives. The program has been reauthorized by Congress every five years, and is currently set to expire unless urgent action is taken. It is absolutely imperative that the House and Senate act swiftly and in unison to ensure that this critical life-saving work continues. Should the program’s authorization lapse at the end of September, there is concern that the program may not be able to operate as efficiently during the continuing public health emergency. My colleagues and I in the House recognize that this federal program provides critical support in the advancement of research for better treatments and the